Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...

The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.

Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45 ...

The market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...

TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin.